1. Home
  2. RA vs PHAT Comparison

RA vs PHAT Comparison

Compare RA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Real Assets Income Fund Inc.

RA

Brookfield Real Assets Income Fund Inc.

HOLD

Current Price

$12.52

Market Cap

712.8M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$9.51

Market Cap

759.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RA
PHAT
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
712.8M
759.7M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
RA
PHAT
Price
$12.52
$9.51
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$19.83
AVG Volume (30 Days)
164.2K
1.2M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
N/A
$93.04
Revenue Next Year
N/A
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$12.50
$8.21
52 Week High
$13.59
$18.31

Technical Indicators

Market Signals
Indicator
RA
PHAT
Relative Strength Index (RSI) 39.65 45.61
Support Level $12.51 $8.46
Resistance Level $13.02 $9.75
Average True Range (ATR) 0.08 0.48
MACD -0.00 0.11
Stochastic Oscillator 18.91 49.44

Price Performance

Historical Comparison
RA
PHAT

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: